Article |

Court criticizes FDA on rejected claims

The Court of Appeals for the D.C. Circuit, considered the most influential court of appeals on regulatory matters, essentially rejected FDA's high-handed approach to denying health claims deemed lacking "significant scientific agreement." It faulted the agency for failing to define "significant scientific agreement" and for refusing even to consider allowing manufacturers to make some label claims as long as they're mitigated by an FDA-approved disclaimer statement.
Print Reprint
FILED IN:  Applications  > Healthcare  > Nutraceutical

The case concerned FDA's outright rejection of four health claims proposed by manufacturers of dietary supplements based on what FDA said was the lack of significant scientific agreement. The scientific support for the claims was inconclusive but the agency refused a proposal that the health claims be accompanied by a disclaimer saying FDA had found the evidence inconclusive. The court's decision left plenty of room for FDA to again reject the health claims but it will have to explain why support for the claims does not reach the threshold of significant scientific agreement and clarify why disclaimers cannot clear up potential consumer confusion. FDA may either ask for a rehearing from the court or a review by the Supreme Court.


Add new comment

Related Sponsored Content

42 Best Package Designs
Sign up to receive timely updates from our editors and download this e-book consisting of our editors' picks of most notable package designs. Updated for 2014!


Don't miss intelligence crucial to your job and business!
Click on any newsletter to view a sample. Enter your email address below to sign up!
Each newsletter ranges in frequency from once per month to a few times per month at most.